{
    "brief_title": "A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer",
    "phase": "Phase 2",
    "drugs": "['TQB3616 capsules', 'Fulvestrant injection']",
    "drugs_list": [
        "TQB3616 capsules",
        "Fulvestrant injection"
    ],
    "diseases": "['HR-positive, HER2-negative Advanced Breast Cancer']",
    "diseases_list": [
        "HR-positive",
        "HER2-negative Advanced Breast Cancer"
    ],
    "enrollment": "120.0",
    "inclusion_criteria": "inclusion criteria: \n\n 1.Understood and signed an informed consent form. 2.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy \u2265 3 months. 3. Histopathologically confirmed HR positive and HER2 negative advanced or metastatic breast cancer. 4.Cohort 1: patients had received \u22641 line of treatment. 5.Cohort 2: patients had not previously received systemic antitumor therapy. 6.Has at least one measurable lesion according to RECIST1.1 criteria. 7.Adequate laboratory indicators. \n\n ",
    "exclusion_criteria": ": \n\n 1. Concomitant disease and medical history: \n\n Has other malignant tumors within 3 years; \n\n Has multiple factors affecting oral medication; \n\n Unalleviated toxicity \u2265 grade 1 due to any previous anticancer therapy; \n\n Has active or uncontrolled severe infections before the first dose; \n\n Cirrhosis, active hepatitis# \n\n Have a history of immunodeficiency; 2. Tumor-related symptoms and treatment: \n\n Has central nervous system metastases (CNS) and/or cancerous meningitis or leptomeningeal carcinomatosis; \n\n Had received chemotherapy within 3 weeks prior to the first dose, and had received radiotherapy , hormone therapy, or other anti-tumor therapy within 2 weeks prior to the first dose; \n\n Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. \n\n 3. Has known to be allergic to Fulvestrant injection , TQB3616 or any excipient. \n\n 4. Has Participated in other clinical trials within 4 weeks before first dose. 5. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.",
    "brief_summary": "This study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort 1 and Cohort 2. Each cohort will enroll 30-60 cases.",
    "NCT_ID": "NCT04796623"
}